Recipharm adds capacity through ViroPharma contract

Related tags Pharmacology

Recipharm adds capacity through ViroPharma contract
Swedish CDMO Recipharm will gain manufacturing capacity through its new production contract with ViroPharma.

Under the deal – which will see Recipharm make commercial supplies of the adrenal insufficiency drug Plenadren – ViroPharma will invest in new tablet manufacturing and active pharmaceutical ingredient (API) coating technology to be installed at the CDMO’s plant in Arsta, Stockholm

The agreement follows Recipharm’s completion of a scale-up contract​ with original Plenadren developer Sweden-based DuoCort, which was acquired by ViroPharma in November for an upfront payment of $33m (€25m).

Helene Fehrm, General Manager at Recipharm Stockholm told that: “we will be able to use the technology for other customers” although the US drugmaker “retains its status as a customer with the highest priority​.”

Related topics Contract Manufacturing & Logistics

Related news

Show more